GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028

Lifesciences | Diagnostic & Biotechnology

GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028

Market by Therapeutics, Diagnostics, and Regional Outlook | Forecast 2022-2028

Request For Customization

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

Alzheimer’s disease (AD) is a progressive, degenerative condition that affects the brain’s neurons and causes memory loss, behavioral abnormalities, and thinking & language impairments. The rising prevalence of this disease is posing a serious threat to the public’s health. There are 5.3 million Alzheimer’s patients in the United States alone, and 35 million worldwide, as per the Translational Research & Clinical Interventions journal.

According to Triton Market Research’s analysis, the Global Alzheimer’s Disease Therapeutics and Diagnostics Market is likely to reach $10991.17 million by 2028 from $6703.50 million in 2021, with a CAGR of 6.98% during the forecast period 2022-2028.


Click here to check out our blog on the Global Alzheimer’s Disease Therapeutics and Diagnostics Market

MARKET PERFORMANCE: DRIVERS, CHALLENGES, AND TRENDS

Over the forecast period, the market’s expansion is likely to be fueled by the significant increase in Alzheimer’s disease prevalence and the rise in the older population. Alzheimer’s disease is one of the most common forms of dementia in the world. A new case of AD is believed to occur every 33 seconds, which accounts for the disease’s extremely high frequency and prevalence in almost 35 million people globally. This has increased the demand to develop clinical diagnostics and therapies for AD and other neurodegenerative disorders.

The market, however, faces significant obstacles like the failure of late-stage medications and strict government regulations. The cholinergic hypothesis of memory impairment was first put forth in 1984, marking the beginning of the present age of medication development for AD. Since then, only 4 cholinesterase inhibitors & memantine have demonstrated effectiveness against Alzheimer’s progression, despite the study of innumerable possible treatments & medications in clinical studies. As a result, the global market for diagnostics and treatments for Alzheimer’s disease has been considerably constrained by the failures of these late-stage medications.

The usage of computed tomography (CT) in the diagnosis of Alzheimer’s disease presents an overall positive outlook for the market. Computed tomography is one of the most advanced & cost-effective diagnostic tests used for the diagnosis of AD. According to Medscape, a CT scan is nearly 20% less expensive compared to an MRI scan. This has increased the demand for CT scans in the Alzheimer’s affected population.



Report scope can be customized per your requirements. Request For Customization 


KEY GEOGRAPHIES COVERED:

•         North America: United States and Canada

•         Europe: United Kingdom, France, Germany, Spain, Italy, and Rest of Europe

•         Asia-Pacific: China, Japan, India, Australia, South Korea, ASEAN Countries, and Rest of Asia-Pacific

•         Latin America: Brazil, Mexico, and Rest of Latin America

•         Middle East and Africa: Saudi Arabia, Turkey, United Arab Emirates, South Africa, and Rest of Middle East & Africa


SEGMENTATION ANALYSIS - ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET

•         Therapeutics is sub-segmented into:

o        By Drug Type

•         Marketed Drugs

•         Pipeline Drugs

o        By Disease Stage

•         Late Stage: Severe AD

•         Early/Middle Stage: Mild to Moderate AD

•         Prodromal Stage

o        By Generic & Branded

•         Branded

•         Generic

Cholinesterase inhibitors, NMDA receptor antagonists, and other medications are marketed drugs in the global Alzheimer’s disease therapeutics and diagnostics market. The drugs that stop the body from breaking down acetylcholine are known as cholinesterase inhibitors or acetylcholinesterase inhibitors. Certain nerve cells have significantly decreased activity in persons with advanced Alzheimer’s disease. This implies that brain signals may not be sent as quickly. Cholinesterase inhibitors work to reduce illness symptoms by enhancing communication between nerve cells.

•         Diagnostics is sub-segmented into:

o        Lumbar Puncture Test

o        Positron Emission Tomography

o        Electroencephalography

o        Magnetic Resonance Imaging

o        Computed Tomography

o        Blood Test

o        Other Diagnostics

The diagnosis of Alzheimer’s disease using a blood test presents a significant market opportunity for diagnostic and treatment products. Alzheimer’s disease can be avoided with a blood test that can spot the disease in its early stages. The condition can potentially be treated with medication if AD is detected in its early stages. Adtect, a newly created blood test, is utilized in the early identification of AD. The test is known as the AD-specific genes signature test and is based on assessing the expression of the chosen genes in the blood.

 

COMPETITIVE LANDSCAPE:

The competitive landscape helps dive into data about the key players in the Alzheimer’s disease therapeutics and diagnostics market. The strategic initiatives for each of the companies considered have been covered in detail.

 

Collaboration (July 2021): Eli Lilly and Company collaborated with Banner Alzheimer’s Institute

Donanemab, an antibody that acts as a modified form of amyloid A and is being studied for the treatment of early Alzheimer’s disease, is being tested in a Phase 3 preventive trial in conjunction with Lilly and the Banner Alzheimer’s Institute.

Product Development (June 2021): EISAI and Biogen Inc declared FDA grant for LECANEMAB (BAN2401)

A revolution therapy designation for LECANEMAB (BAN2401), an anti-amyloid beta proteofibril antibody for the treatment of Alzheimer’s disease, was announced by EISAI and Biogen Inc.


Key Benefits of the Report:

·       Triton Market Research has a collective experience of 25-30 years in the industry, with its analysts and experts encompassing the most infallible research methodology for its market intelligence and industry analysis.

·       Our research methodology helps in achieving a broader consensus of the market size, shape, and industry trends within each industry segment.

·       The strategy adopted in designing the research methodology includes the amalgamation of the information assembled from primary and secondary sources, with the assistance of analytical tools to construct the forecast and predictive models.

·       The scope of the market report comprises the current scenario of the global alzheimer’s disease therapeutics and diagnostic market, along with the detailed overview of the industry outlook, market dynamics, segmentation analysis, regional outlook, and competitive landscape for the period 2022-2028.

 

FAQs:

Q 1) Does this report include the impact of COVID-19 on the Alzheimer’s disease therapeutics and diagnostics market?

The market study has analyzed the impact of COVID-19 on the Alzheimer’s disease therapeutics and diagnostics market qualitatively as well as quantitatively.

Q 2) Which Alzheimer’s disease type is more prevalent?

The majority of the market share was held by late stage: severe AD in 2021. According to alz.org, the US Food and Drug Administration (FDA) has licensed memantine (Namenda) & cholinesterase inhibitors (Razadyne, Exelon, Aricept) as late-stage medications to treat cognitive symptoms (confusion, memory loss, and problems with thinking and reasoning).

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – SUMMARY

2. INDUSTRY OUTLOOK

2.1. TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET

2.2. PHASES AND STERNNESS OF ALZHEIMER’S DISEASE

2.3. KEY INSIGHTS

2.3.1. USAGE OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE

2.3.2. R&D INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA

2.3.3. DEMAND FOR PERSONALIZED MEDICINES 

2.4. IMPACT OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET

2.5. PORTER’S FIVE FORCES ANALYSIS

2.6. MARKET ATTRACTIVENESS MATRIX

2.7. VENDOR SCORECARD

2.8. INDUSTRY COMPONENTS

2.8.1. RESEARCH & DEVELOPMENT (R & D)

2.8.2. RAW MATERIALS

2.8.3. MANUFACTURING

2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS

2.8.5. END-USER

2.9. KEY IMPACT ANALYSIS

2.9.1. EFFECTIVENESS

2.9.2. PRICE

2.9.3. SAFETY

2.10. KEY MARKET STRATEGIES

2.10.1. ACQUISITIONS

2.10.2. PRODUCT LAUNCHES

2.10.3. CONTRACTS & AGREEMENTS

2.10.4. INVESTMENTS & EXPANSIONS

2.11. MARKET DRIVERS

2.11.1. PREVALENCE OF ALZHEIMER’S DISEASE

2.11.2. RISE IN THE ELDERLY POPULATION

2.12. MARKET CHALLENGES

2.12.1. FAILURE OF LATE-STAGE DRUGS

2.12.2. STRINGENT GOVERNMENT REGULATIONS

2.13. MARKET OPPORTUNITIES

2.13.1. EMERGENCE OF NEW DIAGNOSTIC TECHNOLOGIES

2.13.2. GROWING NUMBER OF PIPELINE DRUGS

3. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY THERAPEUTICS

3.1. BY DRUG TYPE

3.1.1. MARKETED DRUGS

3.1.2. PIPELINE DRUGS

3.2. BY DISEASE STAGE

3.2.1. LATE STAGE: SEVERE AD

3.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.2.3. PRODROMAL STAGE

3.3. BY GENERIC & BRANDED

3.3.1. BRANDED

3.3.2. GENERIC

4. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY DIAGNOSTICS

4.1. LUMBAR PUNCTURE TEST

4.2. POSITRON EMISSION TOMOGRAPHY

4.3. ELECTROENCEPHALOGRAPHY

4.4. MAGNETIC RESONANCE IMAGING

4.5. COMPUTED TOMOGRAPHY

4.6. BLOOD TEST

4.7. OTHER DIAGNOSTICS

5. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – REGIONAL OUTLOOK

5.1. NORTH AMERICA

5.1.1. MARKET BY THERAPEUTICS

5.1.1.1. MARKET BY DRUG TYPE

5.1.1.2. MARKET BY DISEASE STAGE

5.1.1.3. MARKET BY GENERIC & BRANDED

5.1.2. MARKET BY DIAGNOSTICS

5.1.3. COUNTRY ANALYSIS

5.1.3.1. UNITED STATES

5.1.3.2. CANADA

5.2. EUROPE

5.2.1. MARKET BY THERAPEUTICS

5.2.1.1. MARKET BY DRUG TYPE

5.2.1.2. MARKET BY DISEASE STAGE

5.2.1.3. MARKET BY GENERIC & BRANDED

5.2.2. MARKET BY DIAGNOSTICS

5.2.3. COUNTRY ANALYSIS

5.2.3.1. UNITED KINGDOM

5.2.3.2. GERMANY

5.2.3.3. FRANCE

5.2.3.4. ITALY

5.2.3.5. SPAIN

5.2.3.6. REST OF EUROPE

5.3. ASIA-PACIFIC

5.3.1. MARKET BY THERAPEUTICS

5.3.1.1. MARKET BY DRUG TYPE

5.3.1.2. MARKET BY DISEASE STAGE

5.3.1.3. MARKET BY GENERIC & BRANDED

5.3.2. MARKET BY DIAGNOSTICS

5.3.3. COUNTRY ANALYSIS

5.3.3.1. CHINA

5.3.3.2. JAPAN

5.3.3.3. INDIA

5.3.3.4. SOUTH KOREA

5.3.3.5. ASEAN COUNTRIES

5.3.3.6. AUSTRALIA AND NEW ZEALAND

5.3.3.7. REST OF ASIA-PACIFIC

5.4. LATIN AMERICA

5.4.1. MARKET BY THERAPEUTICS

5.4.1.1. MARKET BY DRUG TYPE

5.4.1.2. MARKET BY DISEASE STAGE

5.4.1.3. MARKET BY GENERIC & BRANDED

5.4.2. MARKET BY DIAGNOSTICS

5.4.3. COUNTRY ANALYSIS

5.4.3.1. BRAZIL

5.4.3.2. MEXICO

5.4.3.3. REST OF LATIN AMERICA

5.5. MIDDLE EAST AND AFRICA

5.5.1. MARKET BY THERAPEUTICS

5.5.1.1. MARKET BY DRUG TYPE

5.5.1.2. MARKET BY DISEASE STAGE

5.5.1.3. MARKET BY GENERIC & BRANDED

5.5.2. MARKET BY DIAGNOSTICS

5.5.3. COUNTRY ANALYSIS

5.5.3.1. UNITED ARAB EMIRATES

5.5.3.2. TURKEY

5.5.3.3. SAUDI ARABIA

5.5.3.4. SOUTH AFRICA

5.5.3.5. REST OF MIDDLE EAST & AFRICA

6. COMPETITIVE LANDSCAPE

6.1. BAXTER INTERNATIONAL INC

6.2. F. HOFFMANN-LA ROCHE AG

6.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)

6.4. NOVARTIS AG

6.5. PFIZER INC

6.6. SIEMENS HEALTHINEERS AG

6.7. AMARANTUS BIOSCIENCE HOLDINGS INC

6.8. EISAI CO LTD

6.9. ELI LILLY & COMPANY

6.10. LUPIN LIMITED

6.11. MERCK AND CO

6.12. BIOGEN INC

6.13. COGNOPTIX INC

6.14. GE HEALTHCARE

6.15. JOHNSON AND JOHNSON

6.16. SUN PHARMACEUTICALS INDUSTRIES LTD

6.17. TEVA PHARMACEUTICAL INDUSTRIES LTD

6.18. ZYDUS CADILA

7. METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE

7.2. SOURCES OF DATA

7.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: MARKET ATTRACTIVENESS MATRIX      

TABLE 2: VENDOR SCORECARD       

TABLE 3: KEY STRATEGIC DEVELOPMENTS

TABLE 4: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)         

TABLE 5: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)        

TABLE 6: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION) 

TABLE 7: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)  

TABLE 8: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)

TABLE 9: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)         

TABLE 10: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 11: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)    

TABLE 12: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)       

TABLE 13: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)

TABLE 14: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION) 

TABLE 15: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)         

TABLE 16: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 17: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)         

TABLE 18: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)        

TABLE 19: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION) 

TABLE 20: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)  

TABLE 21: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)

TABLE 22: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 23: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)         

TABLE 24: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)       

TABLE 25: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)

TABLE 26: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION) 

TABLE 27: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)

TABLE 28: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 29: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)         

TABLE 30: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)       

TABLE 31: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)

TABLE 32: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION) 

TABLE 33: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)

TABLE 34: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 35: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)        

TABLE 36: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)

TABLE 37: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $ MILLION)         

TABLE 38: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028 (IN $ MILLION)    

TABLE 39: MIDDLE EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)         

List of Figures

FIGURE 1: PORTER’S FIVE FORCES ANALYSIS

FIGURE 2: KEY IMPACT ANALYSIS

FIGURE 3: TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS

FIGURE 4: INDUSTRY COMPONENTS          

FIGURE 5: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021 & 2028 (IN %)

FIGURE 6: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021 & 2028 (IN %)

FIGURE 7: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2028 (IN $ MILLION)

FIGURE 8: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2028 (IN $ MILLION)

FIGURE 9: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021 & 2028 (IN %)

FIGURE 10: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2022-2028 (IN $ MILLION)

FIGURE 11: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2028 (IN $ MILLION)

FIGURE 12: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2028 (IN $ MILLION)

FIGURE 13: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2021 & 2028 (IN %)

FIGURE 14: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $ MILLION)

FIGURE 15: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $ MILLION)

FIGURE 16: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2021 & 2028 (IN %)

FIGURE 17: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2028 (IN $ MILLION)

FIGURE 18: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2028 (IN $ MILLION)

FIGURE 19: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2028 (IN $ MILLION)

FIGURE 20: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2028 (IN $ MILLION)

FIGURE 21: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2028 (IN $ MILLION)

FIGURE 22: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN $ MILLION)

FIGURE 23: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2028 (IN $ MILLION)

FIGURE 24: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021 & 2028 (IN %)    

FIGURE 25: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)   

FIGURE 26: CANADA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 27: UNITED KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)   

FIGURE 28: GERMANY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 29: FRANCE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 30: ITALY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 31: SPAIN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 32: REST OF EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)   

FIGURE 33: CHINA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 34: JAPAN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 35: INDIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 36: SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 37: ASEAN COUNTRIES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)   

FIGURE 38: AUSTRALIA & NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)         

FIGURE 39: REST OF ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)         

FIGURE 40: BRAZIL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 41: MEXICO ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 42: REST OF LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 43: UNITED ARAB EMIRATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)         

FIGURE 44: SAUDI ARABIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 45: TURKEY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 46: SOUTH AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION) 

FIGURE 47: REST OF MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)          

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$2,750.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$4,000.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying